Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank_resource:DB00214_DB01241_nanopub.RAXvGtGnAm2fbu_B7U_ZtyjeYZwL2kWR6_8fdWz-hK-UM#assertion>. }
Showing items 1 to 6 of
6
with 100 items per page.
- drugbank_resource:DB00214_DB01241 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB00214_DB01241 label "DDI between Torasemide and Gemfibrozil - Gemfibrozil, a strong CYP2C9 inhibitor, may increase the serum concentration of Torasemide, a CYP2C9 substrate, by decreasing Torasemide metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Torasemide if Gemfibrozil is initiated, discontinued or dose changed. [drugbank_resource:DB00214_DB01241]" assertion.
- drugbank_resource:DB00214_DB01241 identifier "drugbank_resource:DB00214_DB01241" assertion.
- drugbank_resource:DB00214_DB01241 title "DDI between Torasemide and Gemfibrozil - Gemfibrozil, a strong CYP2C9 inhibitor, may increase the serum concentration of Torasemide, a CYP2C9 substrate, by decreasing Torasemide metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Torasemide if Gemfibrozil is initiated, discontinued or dose changed." assertion.
- drugbank:DB01241 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00214_DB01241 assertion.
- drugbank:DB00214 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00214_DB01241 assertion.